司库奇尤单抗联合窄谱中波紫外线治疗中重度银屑病疗效与安全性评价  

Evaluation of Efficacy and Safety of Secukinumab Combined with Narrow-spectrum Medium-wave Ultraviolet Light in the Treatment of Patients with Moderate-to-Severe Psoriasis

作　　者：段艳琼 翟齐航 胡帅 DUAN Yan-qiong;ZHAI Qi-hang;HU Shuai(Department of Dermatology,990 Hospital of the PLA Joint Logistics Support Force,Zhumadian 463000,China)

机构地区：[1]解放军联勤保障部队第九九○医院皮肤科,驻马店463000

出　　处：《四川解剖学杂志》2023年第4期58-60,共3页Sichuan Journal of Anatomy

摘　　要：目的:研究司库奇尤单抗联合窄谱中波紫外线(NB-UVB)治疗中重度银屑病的疗效与安全性.方法:选择2020年4月至2022年10月本院收治的92例中重度银屑病患者为研究对象.按随机数字表法将其分为联合组(n=46,采用司库奇尤单抗联合NB-UVB治疗)和对照组(n=46,采用NB-UVB治疗).比较两组临床疗效、治疗期间不良反应及治疗前、治疗8周后银屑病面积与严重性指数(PASI)、皮肤病生命质量指数(DLQ1)、CC趋化因子配体20(CCL20)和CC趋化因子受体6(CCR6)水平、皮肤屏障功能指标.结果:联合组临床总有效率高于对照组,差异有统计学意义(P<0.05);治疗8周后,联合组患者PASI、DLQ1评分及血清CCL20、CCR6水平低于对照组,皮肤屏障功能指标变化幅度高于对照组,差异均有统计学意义(P<0.05);治疗期间联合组不良反应发生率与对照组比较,差异无统计学意义(P>0.05).结论:采用司库奇尤单抗联合NB-UVB治疗中重度银屑病患者有利于提高临床疗效,抑制促炎、趋化因子表达,改善皮肤屏障功能,提高生活质量,且具有一定安全性.Objective:To study the efficacy and safety of secukinumab combined with narrow-spectrum medium-wave ultraviolet(NB-UVB)for the treatment of moderate-to-severe psoriasis.Methods:A total of 92 patients with moderate to severe psoriasis admited to our hospital from April 2020 to October 2022 were selected in this study.According to the random number table method,they were divided into a combination group(n=46,treated with secukinumab combined with NB-UVB)and a control group(n=46,treated with NB-UVB).The clinical efficacy and incidence of adverse reactions during treatment were compared between two groups.The psoriasis area and severity index(PASI),dermatological disease quality of life index(DLQ1)score,skin barrier function index,serum tumor CC chemokine ligand 20(CCL20),CC chemokine receptor 6(CCR6)levels were compared between two groups before and after 8 weeks of treatment.Result:The total clinical effective rate of the combined group is higher than that of the control group,there was statistically significant difference(P<0.05).After 8 weeks of treatment,the PASI,DLQ1 scores,serum CCL20 and CCR6 levels in the combination group were lower than those in the control group,and the changes in skin barrier function indicators were greater than those in the control group,there were statistically significant differences(P<O.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of patients with moderate-to-severe psoriasis with secukinumab combined with NB-UVB is beneficial to improve clinical efficacy,inhibit pro-inflammatory and chemokine expression,improve skin barrier function,and improve quality of life,and has a certain degree of safety.

关 键 词：司库奇尤单抗 窄谱中波紫外线 银屑病 疗效 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]